US8036071004
US8036071004
Sarepta Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 2.198.237.000 | 1.901.979.000 | 15.6% |
| Cost of Revenue | 839.605.000 | 319.099.000 | 163.1% |
| Gross Profit | 1.358.632.000 | 1.582.880.000 | 14.2% |
| 2.016.404.000 | 1.364.799.000 | 47.7% | |
| Operating Income | -657.772.000 | 218.081.000 | 401.6% |
| Pretax Income | -702.225.000 | 260.774.000 | 369.3% |
| Net Income Common Stockholders | -713.410.000 | 235.239.000 | 403.3% |
| -- | -- | -- | |
| -- | -- | -- |